UK Biotech Closes €50M Series A for GPCR Drug Discovery

Published

February 17, 2020

UK Biotech Closes €50M Series A for GPCR Drug Discovery

Oxford-based OMass Therapeutics has extended its Series A round by €33M to fund the spectrometry-assisted development of drugs targeting G protein-coupled receptors…

MORERelated News
Novel drug-discovery approach lands big backers
UK-based OMass Therapeutics is leaning on a proprietary form of native mass spectrometry to help develop small-molecule drugs for rare...
OMass Therapeutics: The 21st Century Vertex?
Originally spun out of Oxford University, biotech firm OMass Therapeutics today completed an impressive $100m series B round. CEO Ros...
No ‘easy targets’ for Omass, which adds $95M series B for small-molecule work
OMass Therapeutics Ltd. has raised £75.5 million (US$94.6 million) in a series B round, as it continues to advance five...